Skip to main content

Table 1 Main clinicopathological features of Study Group 1

From: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients

VariableStudy Group 1
(n = 152)
Age:
 Mean age ± SEM65 ± 0.81
 Range41–85
pTNM stage:
 Stage I20 (13.2%)
 Stage II11 (7.2%)
 Stage III111 (73%)
 Stage IV10 (6.6%)
Debulking
 R075 (49.4%)
 R112 (7.9%)
 R265 (42.7%)
Vital status of patients70 (46.1%)